Medicus Pharma's SkinJect Shows 73% Clinical Clearance in Phase 2 BCC Trial
Event summary
- Medicus Pharma's SkinJect microneedle delivery system achieved 73% clinical clearance and 40% histological clearance in the 200-µg treatment cohort for basal cell carcinoma (BCC) in Phase 2 trial SKNJCT-003.
- The placebo active arm (P-MNA) showed 38% clinical clearance, highlighting the biological activity of the microneedle delivery platform itself.
- The company plans to advance regulatory discussions with the FDA and pursue strategic partnerships based on the dataset.
- Medicus completed enrollment of 90 patients in the U.S. for the Phase 2 study in December 2025 and expects an end-of-Phase 2 meeting with the FDA in the first half of 2026.
The big picture
Medicus Pharma's positive Phase 2 results for SkinJect position the company to challenge the surgical standard of care for basal cell carcinoma, the most common cancer worldwide. The microneedle delivery platform's biological activity, even in the placebo arm, underscores its potential as a disruptive technology in dermatologic oncology. The company's partnering-focused model aims to leverage decision-grade data to attract strategic collaborators for late-stage development and commercialization.
What we're watching
- Regulatory Pathway
- Whether the FDA will accept the current dataset as decision-grade evidence for advancing SkinJect toward registration.
- Partnering Strategy
- The pace at which Medicus can secure strategic partnerships, particularly with companies active in dermatology and oncology.
- Clinical Efficacy
- How the additional therapeutic contribution of the drug delivered through SkinJect will be further validated in future studies.
Our editorial coverage:
Related topics